Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150211 | 0.87 | PTGS1 (0.43) | PTGS1SLC7A11CPB2ENPEPGSR | |
| SCHEMBL6039402 | 0.87 | PTGS1 (0.43) | PTGS1SLC7A11CPB2ENPEPGSR | |
| SCHEMBL6891065 | 0.84 | PTGS1 (0.48) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL22331154 | 0.82 | PTGS1 (0.46) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL2675600 | 0.82 | PTGS1 (0.46) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL22331155 | 0.82 | PTGS1 (0.46) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL28065154 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL9123179 | 0.81 | ANPEP (0.35) | PTGS1SLC7A11CTHCPB2LMNA | |
| SCHEMBL111370 | 0.80 | PTGS1 (0.44) | PTGS1SLC7A11CPB2LMNAENPEP | |
| Hydrochloric Acid SCHEMBL22331153 | 0.80 | PTGS1 (0.44) | PTGS1SLC7A11ENPEPANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084836-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | THE UNIVERSITY OF TOLEDO (US) | 2021-08-10 | — | — | US | claimed |
| US-20190270786-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2019-09-05 | — | — | US | claimed |
| WO-2018022937-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-02-01 | — | — | WO | claimed |
| CN-106442758-A | Liquid mass spectrometry method for detecting various amino acids in human blood plasma in underivatized mode | 陈大为 | 2017-02-22 | — | — | CN | claimed |
| EP-1750126-B1 | METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND | AJINOMOTO KK (JP) | 2015-09-16 | — | — | EP | claimed |
| US-20130291138-A1 | METHOD TO ENHANCE YIELD AND PURITY OF HYBRID CROPS | MONSANTO TECHNOLOGY LLC (US) | 2013-10-31 | — | — | US | claimed |
| US-20130074213-A1 | METHODS FOR PRODUCING HYBRID SEED | MONSANTO TECHNOLOGY LLC (US) | 2013-03-21 | — | — | US | claimed |
| CN-101631566-A | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same | KEMPHARM INC | 2010-01-20 | — | — | CN | claimed |
| EP-2109465-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2009-10-21 | — | — | EP | claimed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | claimed |
| WO-2008098151-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| EP-1934354-A2 | METHODS FOR PRODUCING HYBRID SEED | Mosanto Technology, LLC (US) | 2008-06-25 | — | — | EP | claimed |
| US-20070269899-A1 | METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP | AJINOMOTO CO. INC. (JP) | 2007-11-22 | — | — | US | claimed |
| US-20070199095-A1 | Methods for producing hybrid seed | MONSANTO TECHNOLOGY LLC | 2007-08-23 | — | — | US | claimed |
| WO-2007047016-A2 | METHODS FOR PRODUCING HYBRID SEED | MONSANTO TECHNOLOGY, LLC (US) | 2007-04-26 | — | — | WO | claimed |
| EP-1750126-A1 | METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-02-07 | — | — | EP | claimed |
| US-5316930-A | DNA molecules and plant or bacteria cells | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 1994-05-31 | — | — | US | claimed |
| EP-0240332-A2 | Virus resistant plants having antisense RNA | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 1987-10-07 | — | — | EP | claimed |
| EP-0240331-A2 | Virus resistant plants having a viral coat protein | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 1987-10-07 | — | — | EP | claimed |
| EP-0140556-A1 | A T-DNA derived vector | LUBRIZOL GENETICS INC. (US) | 1985-05-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | PTGS1 3470/4885SLC7A11 1102/4885CTH 3633/4885 |
| US-20190270786-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL17A, VIP | PTGS1 1359/4885SLC7A11 2141/4885CTH 1056/4885 |
| US-11084836-B2 | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | TFEB, SQSTM1, BECN1 | PTGS1 2945/4885SLC7A11 377/4885CTH 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.